Todd Bauer - Dissemin

All papers authored by Todd Bauer

This paper was not found in any repository, but could be made available legally by the author.

2024 Geoffrey Liu

, Julien Mazieres

, Jan Stratmann

, Sai-Hong Ignatius Ou, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J. Solomon, Todd M. Bauer

A pragmatic guide for management of adverse events associated with lorlatinib

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2023 Erika P. Hamilton

, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd Bauer

, Janet L. Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova

, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick Mitchell, Jamal Saeh and 2 other authors

Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Upload

Erika P. Hamilton

, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd Bauer

, Janet L. Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova

, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick Mitchell, Jamal Saeh and 2 other authors

Data from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Upload

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer

, Junxian Geng, Teffany Davenport

, Michael Teufel

, Jian Li, Mehdi Lahmar

, Mrinal M. Gounder

Supplementary Figure 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Upload

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer

, Junxian Geng, Teffany Davenport

, Michael Teufel

, Jian Li, Mehdi Lahmar

, Mrinal M. Gounder

Supplementary Figure 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Upload

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer

, Junxian Geng, Teffany Davenport

, Michael Teufel

, Jian Li, Mehdi Lahmar

, Mrinal M. Gounder

Supplementary Methods from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Upload

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer

, Junxian Geng, Teffany Davenport

, Michael Teufel

, Jian Li, Mehdi Lahmar

, Mrinal M. Gounder

Supplementary Table 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Upload

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer

, Junxian Geng, Teffany Davenport

, Michael Teufel

, Jian Li, Mehdi Lahmar

, Mrinal M. Gounder

Supplementary Table 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Upload

Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer

, Junxian Geng, Teffany Davenport

, Michael Teufel

, Jian Li, Mehdi Lahmar

, Mrinal M. Gounder

Data from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Upload

Erika P. Hamilton

, Judy S. Wang

, Amit M. Oza

, Manish R. Patel

, Susanna V. Ulahannan

, Todd Bauer

, Janet L. Karlix

, Jorge Zeron-Medina

, Giulia Fabbri

, Paola Marco-Casanova

, Ganesh Moorthy

, Maureen M. Hattersley

, Gillian M. Littlewood

, Patrick Mitchell

, Jamal Saeh

and 2 other authors

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Upload

Todd M. Bauer

, Kathleen N. Moore

, Janet S. Rader

, Fiona Simpkins

, Alain C. Mita, J. Thaddeus Beck

, Lowell Hart, Quincy Chu, Amit Oza, Anna V. Tinker

, Esteban Rodrigo Imedio

, Sanjeev Kumar, Ganesh Mugundu

, Suzanne Jenkins

, Juliann Chmielecki and 3 other authors

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Upload

Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer

, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen and 5 other authors

Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

Upload

Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer

Data from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

Upload

Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer

Supplementary Figure from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

Upload

This paper is made freely available by the publisher.

Mrinal M. Gounder

, Todd M. Bauer

, Gary K. Schwartz, Amy M. Weise, Patricia LoRusso, Prasanna Kumar, Ben Tao, Ying Hong, Parul Patel, Yasong Lu, Arnaud Lesegretain, Vijaya G. Tirunagaru

, Feng Xu, Robert C. Doebele, David S. Hong

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Download from doi.org

2022 Emerson A. Lim

, Johanna C. Bendell

, Gerald S. Falchook

, Todd M. Bauer

, Charles G. Drake

, Jennifer H. Choe

, Daniel J. George

, Janet L. Karlix

, Susanna Ulahannan

, Kris F. Sachsenmeier

, Deanna L. Russell

, Ganesh Moorthy

, Ben S. Sidders

, Elizabeth A. Pilling

, Huifang Chen

and 5 other authors

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

Upload

Benjamin J. Solomon

, Todd M. Bauer

, Sai-Hong Ignatius Ou

, Geoffrey Liu, Hidetoshi Hayashi

, Alessandra Bearz

, Konstantin Penkov, Yi-Long Wu

, Oscar Arrieta

, Jacek Jassem, Anna M. Calella, Gerson Peltz, Anna Polli, Holger Thurm, Tony Mok

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

Download from doi.org

Timothy A. Yap

, Erika Hamilton

, Todd Bauer

, Ecaterina E. Dumbrava

, Rinath Jeselsohn, Aaron Enke, Sabrina Hurley, Kevin K. Lin

, Jenn Habeck, Heidi Giordano, Geoffrey I. Shapiro

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

Download from doi.org

2020 Alice T. Shaw, Todd M. Bauer

, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna M. Calella, Gerson Peltz, Benjamin J. Solomon

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Todd Bauer